Tetraxetan

Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu) . Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) [1][2][3].

Product Specifications

CAS Number

[60239-18-1]

Product Name Alternative

DOTA

UNSPSC

12352200

Hazard Statement

H302, H315, H319, H335

Target

Biochemical Assay Reagents; Radionuclide-Drug Conjugates (RDCs)

Related Pathways

Antibody-drug Conjugate/ADC Related; Others

Field of Research

Cancer

Purity

99.95

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

O=C(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1

Molecular Formula

C16H28N4O8

Molecular Weight

404.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Orcutt KD, et al. Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imaging Biol. 2011 Apr;13 (2) :215-21. |[2]Decristoforo C, et al. 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging. 2008 Aug;35 (8) :1507-15. |[3]Müller C, et al. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice. J Nucl Med. 2013 Jan;54 (1) :124-31.